SiteOne Therapeutics develops groundbreaking non-opioid treatments for acute, neuropathic, visceral, and musculoskeletal pain.
SiteOne Therapeutics has raised $100.0M in total funding. The most recent round was Series C. The last funding was announced in December 2024.
SiteOne Therapeutics's investors include Wellington Management, NEXT Frontier Capital, OrbiMed, Amgen, Novo Holdings.
SiteOne Therapeutics is headquartered in South San Francisco, United States.
SiteOne Therapeutics develops groundbreaking non-opioid treatments for acute, neuropathic, visceral, and musculoskeletal pain.
SiteOne Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"SiteOne Therapeutics — Funding & Investors." VCBacked, December 18, 2024, https://www.vcbacked.co/company/siteone-therapeutics. Accessed October 30, 2026.
VCBacked. (2024). SiteOne Therapeutics — Funding & Investors. Retrieved October 30, 2026, from https://www.vcbacked.co/company/siteone-therapeutics
{{cite web |title=SiteOne Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/siteone-therapeutics |website=VCBacked |access-date=October 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated